FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
Summary
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness. Covered by 5 outlets: 2 lean left, 2 are centre, 1 are not rated.
Automated summary picked from the outlets' own descriptions.
Who is covering this
-
FDA adds rare vision-loss warning to popular GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic
-
GLP-1 drugs to include new warning about rare eye condition causing sudden blindness, FDA says
The FDA is ordering drugmakers to add a new warning labels on GLP-1 injectables and pills linked to a rare eye condition that can cause sudden blindness.
-
FDA adds rare vision-loss warning to popular GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic.
-
FDA is requiring weight loss drug makers to add a vision loss warning
The warning covers all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, over a rare eye condition called NAION
-
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness - NBC News
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness NBC News US FDA orders new eye risk warnings for Ozempic, Zepbound CNN FDA warns GLP-1 drugs carry potential risk of rare eye condition STAT US regulator orders makers of weight-loss drugs to...
-
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness.
-
Ozempic Zepbound eye risk warnings: Diabetes, weight-loss drugs Novo Nordisk's Ozempic, Wegovy, Eli Lilly's Mounjaro, Zepbound pose potential threat to eye, sudden vision loss, warns US FDA
Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy were under scanner of United States Food and Drug Administration (US FDA).
Related stories
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
FDA scientists opposed Trump administration’s move to ease peptide access
Trump administration says biggest changes coming to infant formula in nearly 30 years
Blood pressure medication recalled nationwide
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
Comments
Comments need JavaScript.